Infectious disease

In vitro and mouse studies suggest Sulonex sulodexide or other heparinoids could help treat sepsis. In mouse endothelial cells pretreated with lipopolysaccharide (LPS), the oral heparinoid Sulonex increased thickness of the endothelial glycocalyx, which is reduced in sepsis, compared with vehicle. In a mouse model of polymicrobial-induced sepsis, subcutaneous Sulonex decreased vascular permeability in the lung and peritoneum and increased survival. Next steps could include testing Sulonex in additional models of sepsis...